Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2016 Jul;46(7):687-91.
doi: 10.1093/jjco/hyw047. Epub 2016 May 9.

Lung stereotactic radiotherapy for oligometastases: comparison of oligo-recurrence and sync-oligometastases

Hideomi Yamashita  1 , Yuzuru Niibe  2 , Takaya Yamamoto  3 , Kuniaki Katsui  4 , Keiichi Jingu  3 , Susumu Kanazawa  4 , Atsuro Terahara  5 , Keiichi Nakagawa  1
Affiliations
Comparative Study

Lung stereotactic radiotherapy for oligometastases: comparison of oligo-recurrence and sync-oligometastases

Hideomi Yamashita et al. Jpn J Clin Oncol. 2016 Jul.

Abstract

Background: Oligometastases can be divided into sync-oligometastases and oligo-recurrence. The difference is whether the primary site is uncontrolled or controlled. The goal of this multicenter study was to evaluate treatment outcomes and factors affecting survival after stereotactic body radiotherapy for pulmonary oligometastases.

Methods: The information after stereotactic body radiotherapy from January 2004 to April 2014 was retrospectively collected. Ninety-six patients (65 males, 31 females) were enrolled. Ten cases (10%) were sync-oligometastases, 79 cases (82%) were oligo-recurrences and 7 (7%) were unclassified oligometastases with <6 months of disease-free interval. The median disease-free interval between initial therapy and stereotactic body radiotherapy was 24 months. The median calculated biological effective dose was 105.6 Gy.

Results: The median follow-up period was 32 months for survivors. The 3-year overall survival and relapse-free survival rates were 53% and 32%, respectively. No Grade 5 toxicity occurred. The median overall survival was 23.9 months for sync-oligometastases and 66.6 months for oligo-recurrence (P = 0.0029). On multivariate analysis, sync-oligometastases and multiple oligometastatic tumors were significant unfavorable factors for both overall survival and relapse-free survival.

Conclusions: In stereotactic body radiotherapy for oligometastatic lung tumors, the state of oligo-recurrence has the potential of a significant prognostic factor for survival.

Keywords: SBRT; oligo-recurrence; pulmonary oligometastases; sync-oligometastases.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Overall survival (OS) curves comparing oligo-recurrence and sync-oligometastases. Oligo-recurrence group achieved statistically significant better OS than that of sync-oligometastases (P = 0.0029).
Figure 2.
Figure 2.
OS curves comparing disease-free interval (DFI) not <24 months and DFI <24 months. DFI not <24 months group achieved statistically significant better OS than that of DFI <24 months (P = 0.0083).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Weichselbaum RR, Hellman S.. Oligometastases revisited. Nat Rev Clin Oncol 2011;8:378–82. - PubMed
    1. Hellman S, Weichselbaum RR.. Oligometastases. J Clin Oncol 1995;13:8–10. - PubMed
    1. Niibe Y, Hayakawa K.. Oligometastases and oligorecurrence: the new era of cancer therapy. Jpn J Clin Oncol 2010;40:107–11. - PMC - PubMed
    1. Niibe Y, Chang JY.. Novel insights of oligometastases and oligo-recurrence and review of the literature. Pulm Med 2012;2012:261096. - PMC - PubMed
    1. Jabbour SK, Daroui P, Moore D, et al. . A novel paradigm in the treatment of oligometastatic non-small cell lung cancer. J Thorac Dis 2011;3:4–9. - PMC - PubMed